It is the industry analysis specialist’s new report, “Anti-Hypertension - Drug Pipeline Analysis and Market Forecasts to 2016"" is an essential source of information and analysis on the global anti-hypertension market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global anti-hypertension market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-hypertension sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by its team of industry experts.
The scope of the report includes: - Annualized global anti-hypertension market revenues data from 2001 to 2009, forecast forward for seven years to 2016. - Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan. - Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class drugs act through new mechanisms of action such as eNOS (Endothelial Nitric Oxide Synthase) couplers, sodium-glucose transport 2 (SGLT2) inhibitors, endothelin antagonists, peroxisome proliferator-activated receptor (PPAR)-gamma agonists and cyclooxygenase-1 (COX-1) inhibitors. - Analysis of the current and future market competition in the global anti-hypertension market. Key future market-players covered are Novartis Ag, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceuticals, Daiichi Sankyo Co. Ltd, GlaxoSmithKline Plc, and Sanofi-Aventis. - Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with anti-hypertension.